With a cancer diagnosis, early detection can be a matter of life and death. At Syantra, that urgency is what drives us, day-in and day-out. And that drive is paying off. We’re changing the way cancer is detected and treated, starting with breast cancer.
Learn more about our blood test for breast cancer screening: Syantra DX™ Breast Cancer.
It’s a blood test for breast cancer screening that’s easy, convenient and accurate.
How does it work?
Syantra DX™ Breast Cancer is a precision medicine tool that measures a panel of gene expression biomarkers from whole blood. It then uses a software package, developed with machine learning, to interpret data and provide a positive or negative result.
Syantra DX™ Breast Cancer is a molecular approach to breast cancer screening that can detect invasive disease at early stages.
Syantra DX™ Breast Cancer has an inferred 98.5% accuracy for women under 50 and a 92.2% accuracy overall in ongoing prospective clinical studies.
Clinical studies are ongoing in Calgary, Canada; Manchester, UK; and Seoul, South Korea.
Through the ongoing IDBC prospective international clinical study (NCT04495244), whole blood samples (2.5 ml) from 2,100 participants are being analyzed using Syantra DX™ Breast Cancer.
The participant group includes women aged 25 to 80 years with no breast surgery in the past year and no previous cancer diagnosis except non-melanoma skin cancer. Blood samples are collected around the time of screening mammography and before any biopsies or surgeries.
One in eight women will develop invasive breast cancer in her lifetime.¹
In 2020, there were 7.8 million women alive who had been diagnosed with breast cancer in the past 5 years.²
About 50% of women have dense or very dense breast tissue, which can result in decreased mammography sensitivity.³
18% of breast cancer diagnoses are women under 50-years-old, below the recommended screening age. ⁴
Breast cancer is the world’s most prevalent cancer.⁵
Syantra DX | Breast Cancer has an inferred 98.5% accuracy for women under 50-years-old in ongoing prospective clinical studies.⁶
Syantra DX™ Breast Cancer has been developed over the past decade and has gone through multiple validations, including an ongoing prospective, blinded international study. This study is enrolling women aged 25-80 years around the time of a screening mammogram. Exclusion criteria include previous cancers and breast surgeries in the past year.
*Results presented at the San Antonio Breast Cancer Symposium on December 8, 2021 from an interim analysis of IDBC Clinical Study samples from 1,107 participants. Performance metrics are reported for the blind test set with 99.5% confidence intervals (CI) computed through an exact binomial test. There is the potential for false negative and false positive results to occur.
As a precision medicine company, quality systems are the backbone of everything we do. We work with regulatory authorities and accrediting organizations worldwide to ensure that our processes and protocols are up-to-date and consistently meet the highest standards. Learn more about our accreditations and regulatory certifications.
Syantra DX™ Breast Cancer is a screening test and may be used as part of the regular screening process. There is the potential for false negative and false positive results to occur. All results should be interpreted by a qualified healthcare provider, and no interventional action should be taken based solely on Syantra DX™ Breast Cancer results.
Interested in learning more about Syantra DX™ Breast Cancer or Syantra Inc.? Contact us through the form below.
2023 | Syantra Inc. | 1-877-331-0516
We value your privacy.
Read about it here
Website and branding by:
IVY Design Inc.
We